Clinical trials located in

Balassagyarmat

Balassagyarmat city is located in Hungary. Currently, 10 clinical trials are being conducted in this city.

Balassagyarmat, nestled on the Ipoly River bordering Slovakia, is a city steeped in history and culture. Once a significant border fortress against Ottoman invasions, it boasts architectural marvels like the neoclassical county hall and the late baroque-style Roman Catholic church. The city is also known for its judicial heritage, hosting the first instance court. Balassagyarmat’s Palóc Museum, dedicated to the local Palóc ethnographic group, showcases the rich cultural tapestry and traditions of the region.

  • CT-EU-00041455

    Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    • Tanimilast/CHF6001
    • Roflumilast
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • Investigating a new inhaler’s impact: comparative study in asthma treatment

    The study is designed to assess whether PT010, a new inhaler, can be beneficial for adults and teenagers with poorly managed asthma. PT010 comprises three active ingredients: budesonide, glycopyrronium, and formoterol. The comparative analysis aims to determine the effectiveness and safety of PT010 in comparison to another inhaler containing budesonide and formoterol, as well as the widely used Symbicort inhaler. The study will span from 24 to 52 weeks and involve approximately, 2200 participants from various locations. The primary focus will be on the improvement of lung function within 24 weeks, alongside evaluating the reduction in the frequency of asthma attacks and its impact on quality of life and respiratory control.

    • Symbicort
    • Budesonide/formoterol fumarate (BFF pMDI)
    • budesonide/glycopyrronium/formoterol (BGF MDI)
  • Benralizumab trial for Chronic Lung Disease (COPD) patients

    This Phase 3 clinical trial evaluates Benralizumab in treating COPD, a severe lung condition characterized by breathing difficulties. It specifically targets individuals who experience frequent flare-ups, despite ongoing medication. The trial requires participants to have had at least two flare-ups in the previous year and a high eosinophil count in their blood. The study involves administering Benralizumab for a minimum of 56 weeks, with the aim to assess its impact on reducing flare-ups and improving lung function.

    • Benralizumab
  • Tozorakimab study for viral lung infection in hospitalized patients needing oxygen

    This clinical trial evaluates the effectiveness and safety of tozorakimab for hospitalized patients with viral lung infections requiring supplemental oxygen. The study involves two groups: one receiving tozorakimab and the other a placebo, alongside standard care. The main goal is to see if tozorakimab can lower the risk of death or the need for intensive respiratory support. The study involves adult patients and aims to measure various health outcomes, including mortality rates and the length of intensive care and oxygen support.

    • Tozorakimab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Study of a new drug in children with shortness of breath and wheezing

    This study focuses on Broncho-Vaxom (OM-85), a medication intended to assist children who frequently experience chest infections and encounter difficulties such as wheezing or shortness of breath. The trial is set up to compare three groups of kids from 6 months to 5 years old. The first group will get Broncho-Vaxom (OM-85) for a whole year, the second group will get OM-85 for three months and then a placebo for nine months, and the third will only get the placebo for a year. Observations will be conducted on the children for a year and a half to assess whether there is a reduction in chest infections while they are taking the medication.

    • Broncho-Vaxom/Bacterial Lysates/OM-85

See more clinical trials in other cities in Hungary:

.